Related Experiment Video
Updated: May 1, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. It has been shown that rituximab exerts cytotoxic activities through CDC and ADCC, and that it directly induces apoptosis. The CD20 protein has four transmembrane domains (tetraspan structure) and is not internalized following antibody binding, and is not shed or secreted into the circulation. Therefore, CD20 can serve as a target of antibody therapy. As the other anti-CD20 antibodies, there are ofatumumab and obinutuzumab, and clinical development is expected. In addition, histone deacetylate inhibitor or proteasome inhibitor as a new drugs for lymphoma in the future.
Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. It has been shown that rituximab exerts cytotoxic activities through CDC and ADCC, and that it directly induces apoptosis. The CD20 protein has four transmembrane domains (tetraspan structure) and is not internalized following antibody binding, and is not shed or secreted into the circulation. Therefore, CD20 can serve as a target of antibody therapy. As the other anti-CD20 antibodies, there are ofatumumab and obinutuzumab, and clinical development is expected. In addition, histone deacetylate inhibitor or proteasome inhibitor as a new drugs for lymphoma in the future.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Modified-Release Drug Delivery Systems: Site-Targeted
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...